ACXP

Conviction 4HealthcareScan · Thu, Jun 25, 2026

ACXP$1.42-3.40%

ResistanceSupportVol 14

Vol MA14 69.86K

Mar 26Apr 14May 1May 19Jun 8Jun 25

Acurx Pharmaceuticals, Inc.PHARMACEUTICAL PREPARATIONSwww.acurxpharma.com ↗

Price1.42

Change-3.40%

Gap-1.70%

Rel volume0.93×

Avg volume75.72K

Avg $ vol125.71K

SMA 201.65

SMA 501.92

SMA 2003.35

Price vs 50-26.13%

Price vs 200-57.66%

MA stackbearish

50/200 cross—

Supertrenddown · 1.77

RSI (14)29

MACD hist0.00

MACD crossbull · 5d

Stoch %K / %D0 / 4

ADX (14)23

+DI / −DI13 / 24

RSI divergence—

MACD divergenceBullish

ATR %+9.17%

ADR %6.57%

52w high8.10

52w low0.2924

From 52w high-82.47%

Above 52w low+385.64%

New 52w highNo

SqueezeOff

Bollinger width40.71%

%B0.16

Donchian pos0.00%

Donchian high2.01

Donchian low1.42

AVWAP (52w high)4.84

vs AVWAP high-70.65%

AVWAP (52w low)4.80

vs AVWAP low-70.43%

OBV trendDown

Chaikin MF (20)-0.41

Today vs 20d0.93×

Avg vol (14d)69.86K

Avg vol (20d)75.72K

Avg $ vol (20d)125.71K

Market cap6.1M

RS 3m (vs SPY)-77.91%

RS 6m (vs SPY)-63.59%

RS line new highNo

Trend template1/8

Technical rank4.6

1 week-7.79%

1 month-26.80%

3 months-66.74%

6 months-58.84%

1 year+125.93%

YTD-48.55%

P/E-0.77

P/B0.87

P/S—

P/FCF—

EPS-5.32

Div yield—

ROE-113.59%

ROA-83.51%

Debt/Eq—

Current2.44

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth43.51%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value-8.36M

Revenue—

Net income-1.68M

Gross profit—

Free cash flow—

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out4.3M

Employees4

ListedFri, Jun 25, 2021

Free float2.53M

Float %88.6%

Short interest90.03K

Days to cover0.9d

Short volume45.3%

Squeeze score15 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction4 / 100

Pattern quality—

Tech rank4.6 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance2.21

Support1.47

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ACXP

All disclosures →

No recent disclosed trades by Congress in ACXP. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ACXP · 8 buys

Insider	Side	Shares	Value	Traded	Filed
LUCI DAVID P President and CEO · Stock Option · 2026-04-20	Grant	37.1K	$0	2026-04-20	2026-04-22
DELUCCIA ROBERT J Director · Stock Option · 2026-04-20	Grant	37.1K	$0	2026-04-20	2026-04-22
Scodari Joseph C Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22
Shawah Robert G. Chief Financial Officer · Stock Option · 2026-04-20	Grant	25.9K	$0	2026-04-20	2026-04-22
HARRISON THOMAS L Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22
Sailer Carl Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22
DEAN JACK H Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22
Donohue James J. Director · Stock Option · 2026-04-20	Grant	2.15K	$0	2026-04-20	2026-04-22

SEC filings

EDGAR filings in ACXP

EDGAR →

No recent SEC filings on file for ACXP.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.